Over the last two decades, we have made leaps and bounds in our understanding of the immune mechanisms in inflammatory disorders including the different allergic and non-allergic pathways that contribute to various endotypes of asthma and chronic rhinosinusitis with nasal polyposis (CRSwNP). Since the first biologic agent for asthma was approved by the Food and Drug Administration [FDA] almost 18 years ago, interest in the development of additional agents to other potential immunologic targets has increased; with this increased attention, further monoclonal antibodies have received FDA approval for asthma and CRSwNP. Understanding inflammatory biomarkers, patient profiles, and immunologic targets can assist with patient and biologic agent selection. Monoclonal antibodies target highly-specific and critical pathways that are essential in the pathogenesis of allergic and respiratory disorders. These agents are changing the treatment paradigms for CRSwNP, asthma, and other allergic and respiratory disorders. It is difficult to keep up with the rapidly expanding scientific literature on the role of biologics in these disorders. This session will review the immune mechanisms involved in the development of CRSwNP and asthma as well as discuss the current and some future biologic agents available for the use in treating asthma and CRSwNP.